Cyclophosphamide is an alkylating agent belonging to the group of oxazaphosporines. As
cyclophosphamide is in clinical use for more than 40 years, there is a lot of experience using …

Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape
should ultimately lead to more subset-specific AML therapies, ideally tailored to each …

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …

Potent immunosuppressive drugs have significantly improved early patient survival after
liver transplantation (LT). However, long‐term results remain unsatisfactory because of …

Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly
used to treat hematologic cancers; however, characteristics of the optimal haploidentical …

Worldwide, each year over 30,000 patients undergo an allogeneic hema-topoietic stem cell
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …

Graft-versus-host disease (GVHD) is the most important complication of allogeneic
hematopoietic stem cell transplantation (alloHSCT). We performed a prospective …

Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …

Natural killer (NK) cells are attractive within adoptive transfer settings in cancer
immunotherapy due to their potential for allogeneic use; their alloreactivity is enhanced …